Who should be screened if I have no symptoms?

USPSTF recommends screening asymptomatic adults aged 35 to 70 years who have overweight or obesity, and referring people with prediabetes to effective prevention. Screening may start earlier, or at a lower BMI, in higher-prevalence groups. CDC materials still treat symptoms such as marked thirst, frequent urination, or unexplained weight loss as reasons for diagnostic testing, not a wellness panel delay.

Do I need fasting insulin or a proprietary metabolic score?

Not as first-line care. Fasting insulin and HOMA-IR can appear in research or selected endocrine visits, but assays and treatment thresholds are less standardized than glucose criteria. A colorful insulin-resistance label does not replace an abnormal A1C or fasting glucose. Ask which result would change a medicine, a dietitian referral, or a CDC-style prevention program this year.

When is an abnormal glucose result an emergency?

Seek urgent care for confusion, vomiting, severe dehydration, very high readings, or signs of diabetic ketoacidosis. Those are medical problems, not longevity-menu questions. For a single unexpected A1C or fasting glucose without severe symptoms, confirm the result as NIDDK advises and see a physician, NP, or PA. Do not start peptides or “metabolic IVs” while skipping indicated diabetes care.

Metabolic Health and Diabetes Testing

Q: Which tests diagnose prediabetes and type 2 diabetes?

USPSTF screening and ADA diagnosis use A1C, fasting plasma glucose, or a 2-hour oral glucose tolerance test. NIDDK publishes the usual cutoffs: diabetes at A1C 6.5 percent or higher, fasting glucose 126 mg/dL or higher, or OGTT 200 mg/dL or higher, usually confirmed. A boutique insulin-resistance score is not a diagnosis and should not start or stop medicine by itself.

Who this is for

This guide is for adults offered a “metabolic health” panel at a longevity clinic, or who want to know whether they have prediabetes or type 2 diabetes. The useful tests are the ones guidelines already name: A1C, fasting plasma glucose, and an oral glucose tolerance test when those are indicated. A boutique insulin-resistance graphic is not a substitute for those criteria.

It is also for people with overweight or obesity who have never had guideline-based screening. USPSTF recommends screening asymptomatic adults aged 35 to 70 years in that group and referring those with prediabetes to effective prevention. CDC pages describe diabetes testing for people with symptoms or risk as ordinary medical care, not an optional upgrade.

This is not a first stop for confusion, vomiting, severe thirst with rapid weight loss, or very high home glucose. Those need urgent licensed evaluation. Pregnancy uses obstetric pathways and different cutoffs.

If you already take metformin, insulin, or another glucose-lowering drug, this page is about add-on testing and monitoring—not a reason to stop treatment because a clinic prefers a narrower “optimal” A1C band. Testing should name a decision you and a physician, NP, or PA can act on.

What options clinics actually offer

Primary care and endocrinology start with A1C, fasting plasma glucose, or OGTT. NIDDK explains that A1C reflects average glucose over about three months and can diagnose type 2 diabetes and prediabetes when the lab method is appropriate. Fasting glucose is a single morning value after an overnight fast. OGTT measures the response to a standard glucose load and can catch abnormalities missed by fasting values alone.

ADA diagnostic pages and NIDDK tables use the same familiar cutoffs for nonpregnant adults. Diabetes is usually A1C 6.5 percent or higher, fasting glucose 126 mg/dL or higher, or 2-hour OGTT 200 mg/dL or higher, typically confirmed. Prediabetes sits below those lines and above the usual normal ranges. Random glucose of 200 mg/dL or higher with classic symptoms can also diagnose diabetes.

Longevity rooms often add fasting insulin, C-peptide, HOMA-IR, continuous glucose monitor “spikes,” metabolomic scores, and proprietary insulin-resistance indexes. Some of those can be research context. Many are sold as if they were diagnoses. Continuous glucose monitoring is established for many people who already have diabetes. Using a sensor in someone without diabetes to ban fruit or sell supplements is not the same as ADA diagnosis.

Lifestyle programs, registered dietitian visits, and CDC-recognized prevention programs are also clinic options. Those have a clearer job than a second unvalidated score: change diet quality, activity, sleep, and weight when relevant, and start indicated medicine.

First-line: A1C, fasting glucose, or OGTT as indicated, plus blood pressure and lipids.
Selected: repeat confirmatory testing, kidney function, and diabetes education after a real diagnosis.
Not a diagnosis: boutique insulin-resistance labels, “metabolic age,” or a single CGM spike after a meal.

What evidence supports

Screening matters because untreated diabetes raises risks of kidney disease, vision loss, nerve damage, and cardiovascular disease. USPSTF concludes with moderate certainty that screening adults in the recommended group, and offering prevention for prediabetes, has a moderate net benefit. The tests it names are A1C, fasting plasma glucose, and OGTT—not a secret fourth assay sold as longevity.

Diagnosis should be reproducible. NIDDK advises that A1C used for diagnosis should come from a venous sample sent to a lab with an NGSP-certified method. A1C can mislead when red-cell turnover is abnormal, after transfusion, with some hemoglobin variants, in late pregnancy, or in certain anemias and kidney disease. In those settings, glucose-based tests are more trustworthy.

Prediabetes is a risk state, not a boutique personality type. CDC prevention pages emphasize structured lifestyle change and, when a clinician recommends it, medicine that has outcome data. Progression risk varies. An A1C of 6.3 percent is not the same as a marketing “insulin resistance” flag with a normal A1C and normal fasting glucose.

Treating numbers without a diagnosis can harm. Aggressive restriction, unneeded peptides, or stacked supplements do not replace metformin, insulin, or GLP-1 therapy when those are indicated. Conversely, a reassuring proprietary score does not cancel an A1C that already meets diabetes criteria. Evidence-based care follows the confirmed glucose disorder, blood pressure, lipids, kidney function, and eye and foot checks—not the prettiest dashboard.

When to see a clinician first

See a physician, NP, or PA before paying for an expanded metabolic menu if you have never had USPSTF-aligned screening, you have symptoms of hyperglycemia, or a prior A1C or glucose was abnormal and nobody confirmed it. The first job is diagnosis and a treatment plan, not another unvalidated index.

Seek urgent or emergency care for possible diabetic ketoacidosis or severe hyperglycemia: vomiting, confusion, deep rapid breathing, extreme thirst, or very high readings with illness. Do not book a cash panel instead. Those are time-sensitive medical problems.

Get licensed care involved before you stop a prescribed diabetes medicine because a clinic said your “optimal” range is tighter than your endocrinologist’s target. Individual A1C goals differ by age, hypoglycemia risk, and comorbidity. NIDDK notes that targets are shared decisions, not a single wellness number.

If you are pregnant, planning pregnancy, or have a history of gestational diabetes, use obstetric and primary-care pathways. Wellness CGM packages are not designed for those decisions. Bring your medication list, including steroids, antipsychotics, and supplements that can affect glucose.

How to judge progress

Judge the plan by decisions and outcomes that guidelines already use. After a new diagnosis, confirmation, education, and a named follow-up date matter more than a second boutique score. For prediabetes, progress is a repeat A1C or fasting glucose on a sensible interval, weight and activity change you can sustain, and enrollment in a real prevention program when offered.

If you have diabetes, A1C timing usually follows treatment intensity—often twice a year when stable, more often when therapy changes. Home glucose or CGM patterns can guide insulin or hypoglycemia risk. They do not replace the diagnostic criteria that got you into care. Watch kidney function, blood pressure, and lipids on the same timeline as your treating clinician.

Set a stop rule for extra markers. After the first cycle, keep tests that changed a medicine, a referral, or a diagnosis. Drop insulin-resistance labels that only feed a supplement stack. A falling marketing score with an ignored A1C of 7.8 percent is not success.

Return to licensed care if symptoms appear or home readings swing widely. Metabolic testing is a tool for finding and treating prediabetes and diabetes.

Metabolic Health and Diabetes Testing

Who this is for

What options clinics actually offer

What evidence supports

When to see a clinician first

How to judge progress

Frequently Asked Questions

References

Guides

For Providers

Company